ENYO Pharma Announces a 39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome

ENYO Pharma ENYO announced that it has received clearance of its Investigational New Drug IND application from the U.S. Food and Drug Administration FDA to initiate a Phase 2 clinical study of Vonafexor a highly selective FXR agonist for the treatment of Alport Syndrome.

Related Keywords

France ,Bpifrance Innobio ,Jacky Vonderscher ,Drug Administration ,European Medicines Agency ,Alport Syndrome ,Investigational New Drug ,Business Wire ,Autosomal Dominant Polycystic Kidney Disease ,Morningside Ventures ,Andera Partners ,Bpifrance Large ,Chronic Kidney Disease ,Orphan Drug Designation ,Iain Dukes ,Media Contact ,Relations Enyopharma ,Enyo Pharma Dr Jacky Vonderscher Iain Dukes Seriesc Financing Fda Clearance Vonafexor Phase 2 Clinical Trial Alport Syndrome Alpestria1 Investigational New Drug Biotechnology Autosomal Dominant Polycystic Kidney Disease Orbimed Morningside Ventures Andera Partners Bpifrance Innobio Large Eyp651 Egfr Orphan Designation ,